 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C24H22FNO |
| Molar mass | 359.444 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
AM-2201 (1-(5-fluoropentyl)-3-(1-naphthoyl)indole) is a recreational designer drug that acts as a potent but nonselective full agonist for the cannabinoid receptor.[3] It is part of the AM series of cannabinoids discovered by Alexandros MakriyannisatNortheastern University.
Convulsions have been reported[4] including at doses as low as 10 mg.[5]
AM-2201 is a full agonist for cannabinoid receptors. Affinities are: with a Ki of 1.0 nM at CB1 and 2.6 nM at CB2.[6] The 4-methyl functional analog MAM-2201 probably has similar affinities.[original research?] AM-2201 has an EC50 of 38 nM for human CB1 receptors, and 58 nM for human CB2 receptors.[7] AM-2201 produces bradycardia and hypothermia in rats at doses of 0.3–3 mg/kg, comparable to the potency of JWH-018 in rats, suggesting potent cannabinoid-like activity.[7]
AM-2201 metabolism differs only slightly from that of JWH-018. AM-2201 N-dealkylation produces fluoropentane instead of pentane (or plain alkanes in general).[citation needed]
A forensic standard of AM-2201 is available, and the compound has been posted on the Forendex website of potential drugs of abuse.[8]
In the United States, AM-2201 is a Schedule I controlled substance.[9]
|
| |||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Receptor (ligands) |
| ||||||||||||||||||||||||||||||
| Transporter (modulators) |
| ||||||||||||||||||||||||||||||
| Enzyme (modulators) |
| ||||||||||||||||||||||||||||||
| Others |
| ||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||
